1月1日上午，粤港澳大湾区今年首趟中欧班列从广州东部公铁联运枢纽增城西站驶出，110个标准集装箱装满电子产品、日用百货等商品，预计14天后抵 达波兰马拉舍维奇。 这趟满载"大湾区制造"的班列，正是区域外贸高质量发展的生动注脚——在复杂多变的国际环境中，作为我国对外开放前沿的粤港澳大湾区，正以新质生 产力为核心驱动力，完成从规模扩张到质量提升的系统性转型，为"十五五"外贸发展筑牢根基。 结构升级显韧性 外贸"含新量"持续攀升 近年来，大湾区外贸顶住全球经济波动、地缘政治冲突等多重压力，实现发展动能的结构性转换，呈现总量稳增、质效齐升的鲜明特征。最新数据印证了 这一态势。2025年，粤港澳大湾区内地九市进出口总额达9.15万亿元，同比增长4.7%，占全国进出口总值的20.1%，对全国外贸贡献超1/4增量，创历史新 高。 龙头领路破局 全球化布局向纵深推进 面对"十五五"开局的新机遇与新挑战，大湾区龙头企业主动作为，通过产能优化、渠道拓展、品牌升级、组织革新等多维布局，在全球市场抢占先机，为 行业树立标杆。 消费电子领域的TCL电子，始终坚守"中高端"及"全球化"战略，构建起全方位海外布局体系。在产能与供应链层面， ...

（来源：南京晨报） 在临床应用中，这台设备展现出广泛的适配性与精准性，适用于肿瘤的早期筛查与精准定性、心血管斑 块稳定性的评估、微小病灶的鉴别诊断等多个临床难点领域和其他紧急情况。例如，在卒中（中风）患 者的急诊救治中，其高速成像能力与卓越的血管显影技术，可快速、清晰评估脑血管情况，为制定抢救 方案争取宝贵时间，显著提升救治成功率。同时，设备支持各体型成人及儿童全身部位的高质量成像， 满足多人群、多部位的精准诊疗需求。 更优体验、更多保障，新一代光谱CT优势显著，检查更快、体验更舒适：高效的扫描和强大的后处理 能力，可缩短部分复杂检查的等待和诊断时间；辐射更低、安全更有保障：搭载先进的低剂量成像技 术，在确保图像质量精准的前提下，最大限度降低辐射剂量，充分保障患者检查安全，尤其适合老年、 儿童等对辐射更敏感的特殊患者群体；诊断更精准、流程更优化：图像细节更清晰、诊断更精准，有助 于避免不必要的重复检查或侵入性检查，提升诊疗效率。 转自：南京晨报 "以前做完CT，心里总有些忐忑，担心辐射影响。现在知道新机器辐射控制得更好，检查过程也快，感 觉安心多了。"一位刚带孩子完成检查的家长说道。"之前检查最怕长时间憋气， ...

Core Insights - Guangdong's foreign trade in 2025 reached 9.49 trillion RMB, a year-on-year increase of 4.4%, maintaining its position as the largest province in China for 40 consecutive years, accounting for 20.9% of the national total [1] - High-tech product exports from Guangdong reached 1.14 trillion RMB, growing by 15%, marking the first time this category surpassed one trillion RMB [1] - Shenzhen's foreign trade enterprises numbered nearly 7,000, the highest in eight years, with a total import and export volume of 1.29 trillion RMB, up 13.6% [1] Group 1: Trade Performance - In 2025, Guangdong's imports totaled 3.46 trillion RMB, an increase of 7.8%, while exports reached 6.03 trillion RMB, growing by 2.5% [1] - Shenzhen's high-tech product exports accounted for nearly 60% of the province's total in this category, reaching a historical high of 1.4 trillion RMB, with an 11.6% year-on-year growth [3] - The total value of Shenzhen's high-tech product exports surpassed 700 billion RMB, with leading categories including measuring instruments, 3D printers, and automotive parts [3] Group 2: Logistics and Infrastructure - Shenzhen Customs implemented measures such as "departure confirmation" and "direct pick-up and loading," leading to a record container throughput of over 35 million TEUs [2] - The cross-border cargo traffic at Shenzhen Bay port exceeded 10,000 vehicles in a single day, reflecting improved logistics efficiency [2] - The "smart logistics" reform at the airport resulted in a 63% increase in operational efficiency, with air cargo throughput surpassing 1 million tons for the first time [2] Group 3: Support for Advanced Manufacturing - Shenzhen Customs launched a "one-stop" customs clearance service for major project equipment imports, covering over 120 billion RMB in equipment value and reducing production time by 50% [4] - A new inspection and supervision model was trialed to support the import of advanced technology and critical components, reducing clearance times by 46% [4] - In the biopharmaceutical sector, a joint regulatory mechanism was established, benefiting 27 research institutions and enterprises, with imports enjoying facilitation measures totaling 33.176 million RMB, a 7.6% increase [4]

Group 1 - The three major indices collectively rose, with the medical equipment sector showing active performance, as evidenced by the CSI All Index Medical Care Equipment and Services Index (H30178) increasing by 0.53% [1] - Notable performers within the index included Tianzhihang, which rose over 14%, Shuoshi Bio, which increased over 9%, and Sanyou Medical, which saw a rise of over 6% [1] - The Medical Equipment ETF (159873) recorded a trading volume exceeding 16 million yuan, with a subscription of 5 million units during the trading session [1] Group 2 - The Medical Equipment ETF has experienced a net inflow of funds for nine consecutive trading days, accumulating a total net inflow of 117 million yuan as of January 20 [1] - The ETF's scale has doubled over the past 20 days, reaching a latest circulating scale of 233 million yuan [1] - The ETF closely tracks the CSI All Index Medical Care Equipment and Services Index, which selects listed companies in the medical care theme to reflect the overall performance of these securities [1] Group 3 - The first human subject implanted with Neuralink's brain-machine interface, Nolan Arbo, reported that the module in his brain can be wirelessly upgraded remotely, similar to Tesla's OTA updates [2] - This marks a historic first where a human brain can be updated without surgery, allowing for performance improvements through software updates [2] - Merge Labs, a Silicon Valley startup, has raised $252 million in seed funding from investors including OpenAI, indicating strong interest in advancements in medical technology [2] Group 4 - Guotai Junan Securities noted that the scale of medical equipment bidding continues to grow, supported by ongoing implementation of equipment upgrade policies, which are expected to drive long-term procurement levels [2] - The report recommends medical equipment companies that are likely to benefit from the performance recovery driven by the implementation of these upgrade policies [2]

Core Insights - The National Healthcare Security Administration (NHSA) has released a guideline to standardize pricing for surgical robots and other innovative medical technologies, addressing the inconsistency in medical service charges across China [1][2] Group 1: Pricing Guidelines for Surgical Technologies - The NHSA's guideline categorizes pricing into three tiers based on the level of surgical robot involvement: navigation, participation, and precision execution [2][3] - A new "remote surgery assistance fee" has been established, allowing experts in resource-rich areas to charge for remote surgeries conducted for patients in other regions [3][4] - The guideline aims to ensure that medical institutions maintain and upload operational data and records, with penalties for non-compliance to ensure quality control [1] Group 2: Market Trends and Innovations - The market share of domestic surgical robots in China has increased from 32.61% in 2023 to 48.89% in 2024, indicating significant advancements in domestic technology [3] - Despite the growth, the participation rate of robots in surgeries in China is only 6.33%, compared to 42% in the United States, highlighting the potential for further utilization of robotic technology in surgical procedures [3] Group 3: Pathology Pricing Guidelines - The NHSA has also established a pricing guideline for pathology services, including 28 pricing items and 3 additional charges, covering the entire process from sampling to diagnosis [6] - The pathology guideline emphasizes the value of technical labor and aims to support the integration of AI in pathology, enhancing data foundations for future applications [6]

Core Insights - The National Healthcare Security Administration (NHSA) has released the "Guidelines for Auxiliary Operation Project Establishment," establishing a unified pricing management framework for surgical robots and precision medical technologies, marking a significant commercial turning point for the industry [1][2] Group 1: Event Overview - The "Guidelines for Auxiliary Operation Project Establishment" will officially take effect on January 20, 2026, focusing on medical technology innovations such as 3D printing, imaging enhancement, energy devices, intraoperative imaging guidance, robotic arms, and remote surgery [1] - The guidelines standardize 37 pricing items, 5 additional charges, and 1 expansion item, aiming to lead the upgrade of medical technologies and transition from traditional treatment to precision medicine [1] Group 2: Industry Impact - The guidelines create a pricing framework for robotic surgeries and remote surgeries, which is expected to drive the industry from quantitative to qualitative development [2] - The pricing model is tiered based on the level of participation and clinical value of surgical robots, encouraging medical institutions to prioritize robotic applications in complex surgeries [2] Group 3: Beneficiary Companies - Tianzhihang is projected to maintain over 40% market share in the domestic orthopedic surgical robot market by 2025, with a significant number of successful bids and a dominant position in the market [3] - The company is expected to optimize its business model further, with rapid increases in surgical volumes leading to growth in consumables and service revenues [3] - MicroPort Robotics is experiencing validation of its globalization strategy, with a significant increase in commercial orders for its core product, the Tumi laparoscopic surgical robot, and is expected to maintain its competitive edge in the domestic market [3]

Core Viewpoint - Aerospace Changfeng announced a projected net loss for 2025, estimating a loss of 170 million to 200 million yuan, which is an improvement compared to the previous year's loss of 245.94 million yuan [2] Financial Performance - The company expects a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -175 million and -205 million yuan, compared to -268.37 million yuan in the same period last year [2] - The anticipated reduction in loss is between 45.94 million and 75.94 million yuan compared to the previous year [2] Business Segments - The primary reasons for the projected loss include underperformance in the high-end medical equipment market and a decline in new contracts for military electronic infrared optics, leading to no improvement in revenue and profit [2] - Despite the challenges, the public safety business has shown initial success in strategic transformation, resulting in increased revenue and improved performance due to the collection of some long-aged accounts receivable [2]

Core Viewpoint - WanDong Medical's stock has shown a mixed performance in recent trading, with a year-to-date increase of 9.11% but a decline of 3.41% over the last five trading days [1] Group 1: Stock Performance - As of January 21, WanDong Medical's stock price reached 17.00 CNY per share, with a market capitalization of 11.95 billion CNY [1] - The stock has experienced a trading volume of 57.24 million CNY and a turnover rate of 0.49% [1] - Year-to-date, the stock has increased by 9.11%, while it has decreased by 3.41% in the last five trading days [1] Group 2: Financial Performance - For the period from January to September 2025, WanDong Medical reported a revenue of 1.189 billion CNY, reflecting a year-on-year growth of 8.73% [2] - The company recorded a net profit attributable to shareholders of -27.21 million CNY, a significant decrease of 123.51% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for WanDong Medical increased to 27,200, up by 1.23% from the previous period [2] - The average number of circulating shares per shareholder decreased by 1.22% to 25,882 shares [2] - The top ten circulating shareholders include notable entities such as HuaBao ZhongZheng Medical ETF and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]

立项指南将"医疗数据、设备运行记录的存储上传"纳入价格构成，手术机器人相关操作项目中，医疗机 构未上传医疗数据和设备运行记录的，将执行减收、标准不低于100 元。本项规则的制定旨在充分释放 终端设备运行与临床效果数据资源价值，助力医保部门、医疗机构、企业等构建疗效与效益评价模型、 量化手术机器人的临床价值，以及赋能手术机器人相关创新技术的持续优化升级。 投资建议：该指南的执行将在各省份全面推进手术机器人等的规范立项和收费价格制定，促进创新技术 的临床普及，驱动终端设备采购和手术辅助需求释放，建议关注国产手术机器人龙头企业天智航、精锋 医疗、微创机器人。 1、 本项指南对手术机器人进行统一的机械臂辅助操作分类规范和远程手术立项，围绕当前手术机器人 技术发展和临床推广制定收费规则。本次立项1）分档次设立了导航、参与执行、精准执行3 个价格项 目，打破手术入路、应用部位、国内外品牌等划分界限，实行与主手术挂钩的系数化收费模式，参与度 更高、功能更全面、执行更精准的手术机器人可获得更高收费系数，引导医疗机构主动将手术机器人优 先应用于复杂手术，防范滥用；2）收费价格遵循"单台设备同时具备以上两项或三项功能的、实际收费 ...

Core Viewpoint - Xinhua Medical has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit year-on-year, indicating potential challenges in the medical device sector [1][2]. Group 1: Stock Performance - On January 21, Xinhua Medical's stock rose by 2.05%, reaching 16.42 CNY per share, with a trading volume of 120 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 9.961 billion CNY [1]. - Year-to-date, Xinhua Medical's stock price has increased by 14.03%, but it has seen a decline of 2.26% over the last five trading days, a rise of 12.16% over the last 20 days, and a modest increase of 1.67% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Medical reported a revenue of 6.978 billion CNY, reflecting a year-on-year decrease of 6.00%, while the net profit attributable to shareholders was 434 million CNY, down 29.61% compared to the previous year [2]. - Since its A-share listing, Xinhua Medical has distributed a total of 9.63 billion CNY in dividends, with 607 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Xinhua Medical was 38,700, a decrease of 1.44% from the previous period, with an average of 15,610 circulating shares per shareholder, which is an increase of 1.46% [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 13.7328 million shares, a decrease of 2.3604 million shares from the previous period, while Hong Kong Central Clearing Limited increased its holdings by 768,900 shares to 8.6891 million shares [3].